Brought to you by 
Hyperion brings in $40mm through Series B
18 Sep 2007
Executive Summary
GI- and hepatic-focused Hyperion Therapeutics raised $40mm in its Series B round, which was led by Sofinnova Ventures, Highland Capital Partners, and NEA, and included WRF Capital. A member each from Sofinnova, Highland, and NEA joined the company's board, as well as the former CEO of CoTherix.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hyperion brings in $40mm through Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice